Widely hailed as the future of phase II drug development, the adaptive I-SPY2 platform trial has set a new benchmark for efficiency, through innovation in trial design and clinical operations.
I-SPY 2 Agent Timeline
The I-SPY 2 TRIAL's ground-breaking adaptive, multi-agent design allows up to five agents (or combinations of agents) to be evaluated in parallel. Click on an agent of interest to view more information about the agent and the results from I-SPY 2.
I-SPY2 Agents
The I-SPY2 Trial's ground-breaking adaptive, multi-agent design allows up to five agents (or combinations of agents) to be evaluated in parallel. Click on an agent of interest to view more information about the agent and the results obtained in I-SPY. Agents in the table below are ordered newest to oldest beast upon date of entry into the study.